Compare Stocks: MBRX, VERU, KPTI, and IXHL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IXHL Incannex Healthcare	$3.44 +1.5%	$3.29	$2.49 ▼ $19.71	$40.62M	6.97	90,590 shs	73,568 shs
KPTI Karyopharm Therapeutics	$1.75 -3.8%	$3.13	$1.24 ▼ $10.99	$41.28M	0.95	1.38 million shs	957,447 shs
MBRX Moleculin Biotech	$0.53 -6.6%	$0.91	$0.16 ▼ $15.75	$11.01M	1.92	1.03 million shs	1.80 million shs
VERU Veru	$2.46 -1.6%	$2.49	$2.05 ▼ $7.33	$42.63M	-1.17	212,025 shs	93,999 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IXHL Incannex Healthcare	+1.47%	-9.47%	-4.97%	+7.50%	-82.93%
KPTI Karyopharm Therapeutics	-3.85%	+2.94%	-5.91%	-81.50%	-76.60%
MBRX Moleculin Biotech	-6.57%	-28.66%	-13.36%	-82.34%	-95.09%
VERU Veru	-1.60%	+6.03%	-5.02%	-16.33%	-27.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IXHL Incannex Healthcare	$3.44 +1.5%	$3.29	$2.49 ▼ $19.71	$40.62M	6.97	90,590 shs	73,568 shs
KPTI Karyopharm Therapeutics	$1.75 -3.8%	$3.13	$1.24 ▼ $10.99	$41.28M	0.95	1.38 million shs	957,447 shs
MBRX Moleculin Biotech	$0.53 -6.6%	$0.91	$0.16 ▼ $15.75	$11.01M	1.92	1.03 million shs	1.80 million shs
VERU Veru	$2.46 -1.6%	$2.49	$2.05 ▼ $7.33	$42.63M	-1.17	212,025 shs	93,999 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IXHL Incannex Healthcare	+1.47%	-9.47%	-4.97%	+7.50%	-82.93%
KPTI Karyopharm Therapeutics	-3.85%	+2.94%	-5.91%	-81.50%	-76.60%
MBRX Moleculin Biotech	-6.57%	-28.66%	-13.36%	-82.34%	-95.09%
VERU Veru	-1.60%	+6.03%	-5.02%	-16.33%	-27.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IXHL Incannex Healthcare	2.00	Hold	$18.00	423.26% Upside
KPTI Karyopharm Therapeutics	2.57	Moderate Buy	$11.50	557.14% Upside
MBRX Moleculin Biotech	2.33	Hold	$3.00	468.29% Upside
VERU Veru	2.33	Hold	$24.50	895.93% Upside

Current Analyst Ratings Breakdown

Latest MBRX, VERU, KPTI, and IXHL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/28/2026	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$3.00
8/27/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Negative
7/31/2026	KPTI Karyopharm Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$7.00
7/31/2026	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$3.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IXHL Incannex Healthcare	$90K	457.52	N/A	N/A	$2.07 per share	1.66
KPTI Karyopharm Therapeutics	$146.07M	0.27	N/A	N/A	($16.00) per share	-0.11
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$4.69 per share	N/A
VERU Veru	$16.89M	2.48	N/A	N/A	$1.25 per share	1.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IXHL Incannex Healthcare	-$46.88M	-$1.55	N/A	N/A	N/A	N/A	-81.01%	-76.11%	9/23/2026 (Estimated)
KPTI Karyopharm Therapeutics	-$196.04M	-$13.09	N/A	N/A	N/A	-153.28%	N/A	-145.18%	11/2/2026 (Estimated)
MBRX Moleculin Biotech	-$33.56M	-$7.13	N/A	N/A	N/A	N/A	-143.51%	-24.53%	11/12/2026 (Estimated)
VERU Veru	-$22.73M	-$0.69	N/A	N/A	N/A	N/A	-47.58%	-35.83%	11/26/2026 (Estimated)

Latest MBRX, VERU, KPTI, and IXHL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/23/2026	Q4 2026	IXHL Incannex Healthcare	$0.13	N/A	N/A	N/A	$0.20 million	N/A
8/13/2026	Q2 2026	KPTI Karyopharm Therapeutics	-$1.37	-$2.32	-$0.95	-$2.32	$32.19 million	$33.43 million
8/13/2026	Q2 2026	MBRX Moleculin Biotech	-$1.55	-$1.40	+$0.15	-$1.40	N/A	N/A
8/10/2026	Q3 2026	VERU Veru	-$0.32	-$0.30	+$0.02	-$0.30	$1.70 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IXHL Incannex Healthcare	N/A	41.56	41.56
KPTI Karyopharm Therapeutics	N/A	0.79	0.76
MBRX Moleculin Biotech	N/A	0.94	0.94
VERU Veru	N/A	4.42	4.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IXHL Incannex Healthcare	0.43%
KPTI Karyopharm Therapeutics	66.44%
MBRX Moleculin Biotech	15.52%
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
IXHL Incannex Healthcare	1.33%
KPTI Karyopharm Therapeutics	1.68%
MBRX Moleculin Biotech	18.04%
VERU Veru	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IXHL Incannex Healthcare	12	11.97 million	11.81 million	Not Optionable
KPTI Karyopharm Therapeutics	228	22.68 million	22.30 million	Optionable
MBRX Moleculin Biotech	17	19.48 million	15.96 million	Not Optionable
VERU Veru	230	17.05 million	14.63 million	Optionable

MBRX, VERU, KPTI, and IXHL Headlines

Recent News About These Companies

Veru (NASDAQ:VERU) Stock Rating Upgraded by Wall Street Zen

September 19, 2026 | americanbankingnews.com

Veru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic Cancer

September 8, 2026 | rttnews.com

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant ...

September 8, 2026 | finance.yahoo.com

Veru refocuses sabizabulin on post-daraxonrasib oncology

September 8, 2026 | tipranks.com

Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan

September 8, 2026 | quiverquant.comQ

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

September 8, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

September 2, 2026 | globenewswire.com

Veru (VERU) Q3 2026 Earnings Call Transcript

August 17, 2026 | finance.yahoo.com

Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients

August 10, 2026 | seekingalpha.com

Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239

August 10, 2026 | quiverquant.comQ

Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline

August 10, 2026 | quiverquant.comQ

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

August 10, 2026 | globenewswire.com

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

August 4, 2026 | globenewswire.com

Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update

August 3, 2026 | quiverquant.comQ

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

August 3, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

July 30, 2026 | globenewswire.com

Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity

July 27, 2026 | quiverquant.comQ

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

July 27, 2026 | globenewswire.com

Palisade's Dan Veru talks his small cap trading playbook

July 12, 2026 | cnbc.com

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

July 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, VERU, KPTI, and IXHL Company Descriptions

Incannex Healthcare NASDAQ:IXHL

$3.44 +0.05 (+1.47%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.44 +0.00 (+0.09%)

As of 09/23/2026 07:55 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Karyopharm Therapeutics NASDAQ:KPTI

$1.75 -0.07 (-3.85%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.74 -0.01 (-0.46%)

As of 09/23/2026 08:00 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Moleculin Biotech NASDAQ:MBRX

$0.53 -0.04 (-6.57%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.50 -0.02 (-4.53%)

As of 09/23/2026 07:58 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Veru NASDAQ:VERU

$2.46 -0.04 (-1.60%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.44 -0.02 (-1.02%)

As of 09/23/2026 07:40 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MBRX, VERU, KPTI, and IXHL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MBRX, VERU, KPTI, and IXHL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MBRX, VERU, KPTI, and IXHL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, VERU, KPTI, and IXHL Company Descriptions

Incannex Healthcare NASDAQ:IXHL

Karyopharm Therapeutics NASDAQ:KPTI

Moleculin Biotech NASDAQ:MBRX

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MBRX, VERU, KPTI, and IXHL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MBRX, VERU, KPTI, and IXHL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MBRX, VERU, KPTI, and IXHL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, VERU, KPTI, and IXHL Company Descriptions

Incannex Healthcare NASDAQ:IXHL

Karyopharm Therapeutics NASDAQ:KPTI

Moleculin Biotech NASDAQ:MBRX

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools